Skip to main content
OpenTrials
Completed

NCT Number: NCT02350023

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dept of Dermatology, PGIMER

Chandigarh, 160012, India

About this study

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area
  • Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days

Exclusion criteria

  • • Pregnant and lactating women
  • Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month
  • Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)
  • Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)
  • Extensive disease i.e. >5 patches of AA or area involving >40% area / alopecia totalis/ alopecia universalis/ ophiasis

Treatment and study plan

Topical latanoprost 0.005%

Drug

Local application of the drug on affected skin/scalp

Topical betamethasone 0.05%

Drug

Local application of the drug on affected skin/scalp

Primary outcomes

  1. Number of patients with hair regrowth (complete, partial, or no regrowth)

    Time frame: 4 months

    Response to the treatment in terms of hair regrowth will be assessed. The reduction in the area affected by alopecia areata will be assessed for each patient

Secondary outcomes

  1. Number of patients suffering from adverse effects

    Time frame: 4 months

    The adverse effects of the study drugs will be assessed including erythema, pruritus, skin atrophy, dermatitis, telangiectasia, and others

Sponsors and collaborators

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Other

Registry information

Official study title

A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata

Acronym: COLA

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jan 29, 2015
Registry last updated
Dec 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.